Short Summary
Azurity Pharmaceuticals failed to convince the PTAB that EXELIXIS's drug formulation patent was unpatentable, resulting in a denial of institution for IPR2025-00210. The Board rejected anticipation arguments based on prior art family relationships and dismissed obviousness claims regarding impurity control.
Detailed Summary
The Petitioner, Azurity Pharmaceuticals, Inc., sought to invalidate EXELIXIS, INC.'s patent (11298349) covering drug formulation/process chemistry via Inter Partes Review (IPR). The Board denied institution because the Petitioner failed to demonstrate a reasonable likelihood of success. Specifically, regarding anticipation under 102, the Board ruled that prior art cited from the same patent family did not qualify as effective prior art against the '349 patent. Furthermore, while the Petitioner argued obviousness (103) by combining Brown, Kubo, and Remington to control a specific impurity, the Patent Owner successfully countered this by citing district court findings regarding the lack of motivation for such control under the cited process.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Azurity Pharmaceuticals, Inc. vs EXELIXIS, INC. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Meta Platforms, Inc.vsSitnet, LLC
Meta Platforms challenges Sitnet's patent (8249932) in a PTAB petition, arguing that key claims related to targeted advertising and social networking are obvious. The petitioner asserts that combinations of prior art from Amidon, Walsh, Shahine, and Jones render the challenged claims unpatentable under 103.
Samsung Electronics Co., Ltd. et al.vsWilus Institute of Standards and Technology Inc.
Samsung challenges Wilus’s request for Director Review of the IPR institution, arguing examiner error and consistent claim constructions. The petitioner seeks denial of the review so the IPR can proceed.
Google LLCvsSecure Communication Technologies, LLC
Google petitions the PTAB to invalidate claims of U.S. Patent 8,116,749, arguing they are anticipated and obvious over prior‑art systems that use dynamic device identifiers and a central server.
Dabico Airport Solutions Inc. et al.vsAXA POWER APS et al.
The PTAB denied Dabico Airport’s request for Director Review of a denied institution decision, leaving AXA Power’s patent in force.
Liberty Energy Inc. et al.vsU.S. Well Services, LLC et al.
Liberty Energy has petitioned the PTAB to institute an IPR against U.S. Well Services’ hydraulic fracturing patent, arguing that claims 1‑14 are obvious over multiple prior‑art references. The petition seeks cancellation of all challenged claims under 35 U.S.C. §103.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.